Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria C Cid

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
Annals of the Rheumatic Diseases|March 12, 2025
The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritisMarc Corbera-Bellalta, Farah Kamberovic, Roser Alba-Rovira, et al.
Annals of the Rheumatic Diseases|August 10, 2014
Authors' response to the eLetter by Moiseev et alSergio Prieto-González, Marina Depetris, Ana García-Martínez, et al.
Annals of the Rheumatic Diseases|February 13, 2026
A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritisJean-Paul Makhzoum, Maria C Cid, Maxime Samson, et al.
Annals of the Rheumatic Diseases|March 26, 2014
Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control studySergio Prieto-González, Marina Depetris, Ana García-Martínez, et al.
Journal of Autoimmunity|May 16, 2024
Decoding CD4<sup>+</sup> T cell transcriptome in giant cell arteritis: Novel pathways and altered cross-talk with monocytesElkyn Estupiñán-Moreno, José Hernández-Rodríguez, Tianlu Li, et al.
Medicine|March 4, 2016
Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell ArteritisJosé Hernández-Rodríguez, Giuseppe Murgia, Irama Villar, et al.
Annals of the Rheumatic Diseases|January 20, 2022
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritisMarc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, et al.
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Annals of the Rheumatic Diseases|March 10, 2022
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trialMaria C Cid, Sebastian H Unizony, Daniel Blockmans, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Annals of the Rheumatic Diseases|March 12, 2025
The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritisMarc Corbera-Bellalta, Farah Kamberovic, Roser Alba-Rovira, et al.
Annals of the Rheumatic Diseases|August 10, 2014
Authors' response to the eLetter by Moiseev et alSergio Prieto-González, Marina Depetris, Ana García-Martínez, et al.
Annals of the Rheumatic Diseases|February 13, 2026
A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritisJean-Paul Makhzoum, Maria C Cid, Maxime Samson, et al.
Annals of the Rheumatic Diseases|March 26, 2014
Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control studySergio Prieto-González, Marina Depetris, Ana García-Martínez, et al.
Journal of Autoimmunity|May 16, 2024
Decoding CD4<sup>+</sup> T cell transcriptome in giant cell arteritis: Novel pathways and altered cross-talk with monocytesElkyn Estupiñán-Moreno, José Hernández-Rodríguez, Tianlu Li, et al.
Medicine|March 4, 2016
Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell ArteritisJosé Hernández-Rodríguez, Giuseppe Murgia, Irama Villar, et al.
Annals of the Rheumatic Diseases|January 20, 2022
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritisMarc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, et al.
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Annals of the Rheumatic Diseases|March 10, 2022
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trialMaria C Cid, Sebastian H Unizony, Daniel Blockmans, et al.
Pageof 15